Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Statins Enhance the Efficacy of Pegylated Interferon-alpha2 in Patients with Ph-Negative Chronic Myeloproliferative Neoplasms. Results from a Danish Single-Institution Cohort Study

Isabella Diana Hansen, Morten Kranker Larsen, Vibe Skov, Lasse Kjær, Christina Ellervik, Anders Lindholm Sørensen, Trine Alma Knudsen, Sarah Friis Christensen, Sabrina Cordua, Christina Schjellerup Eickhardt-Dalbøge, Troels Wienecke, Marie Hvelplund Kristiansen, Hans C. Hasselbalch

Blood (2024) 144 (Supplement 1): 3184.

https://doi.org/10.1182/blood-2024-203051

Published: 2024

Journal Articles

Identification of Calr Mutations in Individuals of the Background Population Reveals Undiagnosed Myeloproliferative Neoplasms and Surprisingly Stable Low Levels of Calr Mutant Allele Burden in Individuals Not Developing Myeloproliferative Neoplasm during 10-14 Year Follow-up

Lasse Kjær, Morten Kranker Larsen, Vibe Skov, Trine Alma Knudsen, Sabrina Cordua Bech, Jordan A. Snyder, Johanne Gudmand-Høyer, Morten Andersen, Johnny T. Ottesen, Thomas Stiehl, Christina Ellervik, Hans C. Hasselbalch

Blood (2024) 144 (Supplement 1): 1806.

https://doi.org/10.1182/blood-2024-210127

Published: 2024

Journal Articles

Circulating Extracellular Matrix Fragments As Biomarkers in Myeloproliferative Neoplasms - Baseline Data from the Daliah Trial

Caroline Norup Bistrup, Morten Kranker Larsen, Peter Junker, Vibe Skov, Lasse Kjær, Trine Alma Knudsen, Morten Karsdal, Nicholas Willumsen, Hans C. Hasselbalch

Blood (2024) 144 (Supplement 1): 4545.

https://doi.org/10.1182/blood-2024-200727

Published: 2024

Journal Articles

Final Analysis of the Daliah Trial: A Randomized Phase III Trial of Interferon-α Versus Hydroxyurea in Patients with MPN

Blood (2023) 142 (Supplement 1): 746.

https://doi.org/10.1182/blood-2023-173127

Published: 2023

Journal Articles

Patients with Essential Thrombocythemia Have a Gut Microbiota That Differs from Healthy Controls

Christina Schjellerup Schjellerup Eickhardt-Dalbøge, Anna Cäcilia Ingham, Lee O'Brien Andersen, Henrik V Nielsen, Kurt Fuursted, Christen Rune Stensvold, Morten Kranker Larsen, Lasse Kjær, Sarah F. Christensen, Trine A. Knudsen, Vibe Skov, Christina Ellervik, Lars Rønn Olsen, Hans Carl Hasselbalch, Xiaohui Chen Nielsen, Jens Jørgen Elmer Christensen

Blood (2022) 140 (Supplement 1): 12178–12179.

https://doi.org/10.1182/blood-2022-166031

Published: 2022

Journal Articles

Interferon-alpha2 Treatment Reduces Circulating Neutrophil Extracellular Trap Levels in Myeloproliferative Neoplasms

Laura Massarenti, Trine A. Knudsen, Christian Enevold, Vibe Skov, Lasse Kjær, Morten Kranker Larsen, Claus Henrik Nielsen, Hans Carl Hasselbalch

Blood (2022) 140 (Supplement 1): 3862–3863.

https://doi.org/10.1182/blood-2022-157936

Published: 2022

Journal Articles

Prevalence of the JAK2V617F Mutation in Patients with Ischemic Stroke

Marie H. Kristiansen, Vibe Skov, Lasse Kjær, Morten Kranker Kranker Larsen, Christina Ellervik, Hans Carl Hasselbalch, Troels Wienecke

Blood (2022) 140 (Supplement 1): 3949–3950.

https://doi.org/10.1182/blood-2022-156629

Published: 2022

Journal Articles

Neutrophil-to-Lymphocyte Ratio As a Predictor of All-Cause Mortality in the General Population and Patients with Myeloproliferative Neoplasms

Morten Kranker Kranker Larsen, Vibe Skov, Lasse Kjær, Henrik E. Poulsen, Christina S. Eickhardt-Dalbøge, Trine A. Knudsen, Sarah F. Christensen, Anders L. Sørensen, Marie H. Kristiansen, Troels Wienecke, Rasmus K. Pedersen, Morten Andersen, Johnny T. Ottesen, Thomas Stiehl, Christina Ellervik, Hans Carl Hasselbalch

Blood (2022) 140 (Supplement 1): 6842–6843.

https://doi.org/10.1182/blood-2022-165252

Published: 2022

Journal Articles

Combination Therapy with Ruxolitinib and Interferon in Newly Diagnosed Patients with Polycythemia Vera

Anders Lindholm Lindholm Sørensen, Vibe Skov, Lasse Kjær, Christina Schjellerup Schjellerup Eickhardt-Dalbøge, Morten Kranker Larsen, Claus Nielsen, Carsten Thomsen, Lise Mette Rahbek Gjerdrum, Trine Alma Knudsen, Christina Ellervik, Ulrik Malthe Overgaard, Christen Lykkegaard Andersen, Mads Emil Bjørn, Hans Carl Hasselbalch

Blood (2022) 140 (Supplement 1): 6806–6807.

https://doi.org/10.1182/blood-2022-157397

Published: 2022

Journal Articles

Interferon-alpha2 Favorably Impacts Deregulated Atherosclerosis Genes in Polycythemia Vera and Related Neoplasms

Vibe Skov, Mads Thomassen, Lasse Kjær, Morten Kranker Larsen, Christina Ellervik, Trine Alma Knudsen, Torben A. Kruse, Hans Carl Hasselbalch

Blood (2022) 140 (Supplement 1): 9604–9605.

https://doi.org/10.1182/blood-2022-157906

Published: 2022

Journal Articles

Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial

Blood (2022) 140 (Supplement 1): 1794–1796.

https://doi.org/10.1182/blood-2022-156445

Published: 2022

Journal Articles

The Gut Microbiota in Patients with Polycythemia Vera: Novel Vs. Conventional Treatments

Christina Schjellerup Schjellerup Eickhardt-Dalbøge, Anna Cäcilia Ingham, Lee O'Brien Andersen, Henrik V Nielsen, Kurt Fuursted, Morten Kranker Larsen, Lasse Kjær, Sarah Friis Christensen, Trine Alma Knudsen, Vibe Skov, Christina Ellervik, Hans C. Hasselbalch, Jens Jørgen Elmer Christensen, Xiaohui Chen Nielsen

Blood (2021) 138 (Supplement 1): 1501.

https://doi.org/10.1182/blood-2021-148350

Published: 2021

Journal Articles

Superiority of IFN Versus HU Using a Novel Biomarker-Based Tool for Assessment of Disease Burden in MPNs

Vibe Skov, PhD, Marc JB Dam, Rasmus K Pedersen, Morten Andersen, PhD, Trine Alma Knudsen, MD, Zamra Sajid, Lasse Kjær, PhD, Christina Ellervik, MD PhD, Hans Hasselbalch, MD, Johnny T Ottesen, PhD

Blood (2019) 134 (Supplement_1): 2972.

https://doi.org/10.1182/blood-2019-126819

Published: 2019

Journal Articles

Significantly Upregulated Thrombo-Inflammatory Genes Are Normoregulated or Significantly Downregulated during Treatment with Interferon-Alpha2 in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Vibe Skov, PhD, Caroline Riley, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Thomas Stauffer Larsen, MD PhD, Torben A Kruse, Hans Hasselbalch, MD

Blood (2019) 134 (Supplement_1): 2978.

https://doi.org/10.1182/blood-2019-131698

Published: 2019

Journal Articles

Highly Deregulated Fibulins in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Vibe Skov, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Thomas Stauffer Larsen, MD PhD, Torben A Kruse, Hans Hasselbalch, MD

Blood (2019) 134 (Supplement_1): 5396.

https://doi.org/10.1182/blood-2019-130560

Published: 2019

Journal Articles

Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response

Blood (2019) 134 (Supplement_1): 4202.

https://doi.org/10.1182/blood-2019-126164

Published: 2019

Journal Articles

Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population

Sabrina Cordua, Lasse Kjaer, Vibe Skov, Niels Pallisgaard, Hans C. Hasselbalch, Christina Ellervik

Blood (2019) 134 (5): 469–479.

https://doi.org/10.1182/blood.2019001113

Published: 2019

Includes: Supplemental data

Journal Articles

Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Impacts Deregulation of Oxidative Stress Genes and Antioxidative Defence Mechanisms. Potential Implications of IFN-Alfa Induced Changes in TP53, NRF2 and CXCR4 for Genomic Instability and CD34+ Mobilisation

Vibe Skov, PhD, Caroline Riley, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Thomas Stauffer Larsen, MD PhD, Ole Weis Bjerrum, MD PhD, Torben A Kruse, Hans Carl Hasselbalch, Professor, dr.MD

Blood (2018) 132 (Supplement 1): 4326.

https://doi.org/10.1182/blood-2018-99-112109

Published: 2018

Journal Articles

The Impact of the Mutational Landscape upon the Molecular Responses to Interferon-Alfa2 in Calr-Mutated MPN Patients

Vibe Skov, PhD, Lasse Kjær, PhD, Mads Thomassen, PhD, Steffen Koschmieder, MD, Julia Czech, Nicolas Chatain, PhD, Niels Pallisgaard, Sabrina Cordua, MD, Torben A Kruse, Hans Carl Hasselbalch, Professor, dr.MD

Blood (2018) 132 (Supplement 1): 4327.

https://doi.org/10.1182/blood-2018-99-119158

Published: 2018

Journal Articles

The Impact of Interferon on Interferon-Related Genes in Polycythemia Vera and Allied Neoplasms

Vibe Skov, PhD, Caroline Riley, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Thomas Stauffer Larsen, MD PhD, Ole Weis Bjerrum, Torben A Kruse, Hans Carl Hasselbalch, Professor, dr.MD

Blood (2018) 132 (Supplement 1): 4328.

https://doi.org/10.1182/blood-2018-99-110602

Published: 2018

NARROW

Statins Enhance the Efficacy of Pegylated Interferon-alpha2 in Patients with Ph-Negative Chronic Myeloproliferative Neoplasms. Results from a Danish Single-Institution Cohort Study

Identification of Calr Mutations in Individuals of the Background Population Reveals Undiagnosed Myeloproliferative Neoplasms and Surprisingly Stable Low Levels of Calr Mutant Allele Burden in Individuals Not Developing Myeloproliferative Neoplasm during 10-14 Year Follow-up

Circulating Extracellular Matrix Fragments As Biomarkers in Myeloproliferative Neoplasms - Baseline Data from the Daliah Trial

Final Analysis of the Daliah Trial: A Randomized Phase III Trial of Interferon-α Versus Hydroxyurea in Patients with MPN

Patients with Essential Thrombocythemia Have a Gut Microbiota That Differs from Healthy Controls

Interferon-alpha2 Treatment Reduces Circulating Neutrophil Extracellular Trap Levels in Myeloproliferative Neoplasms

Prevalence of the JAK2V617F Mutation in Patients with Ischemic Stroke

Neutrophil-to-Lymphocyte Ratio As a Predictor of All-Cause Mortality in the General Population and Patients with Myeloproliferative Neoplasms

Combination Therapy with Ruxolitinib and Interferon in Newly Diagnosed Patients with Polycythemia Vera

Interferon-alpha2 Favorably Impacts Deregulated Atherosclerosis Genes in Polycythemia Vera and Related Neoplasms

Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial

The Gut Microbiota in Patients with Polycythemia Vera: Novel Vs. Conventional Treatments

Superiority of IFN Versus HU Using a Novel Biomarker-Based Tool for Assessment of Disease Burden in MPNs

Significantly Upregulated Thrombo-Inflammatory Genes Are Normoregulated or Significantly Downregulated during Treatment with Interferon-Alpha2 in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Highly Deregulated Fibulins in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response

Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population

Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Impacts Deregulation of Oxidative Stress Genes and Antioxidative Defence Mechanisms. Potential Implications of IFN-Alfa Induced Changes in TP53, NRF2 and CXCR4 for Genomic Instability and CD34+ Mobilisation

The Impact of the Mutational Landscape upon the Molecular Responses to Interferon-Alfa2 in Calr-Mutated MPN Patients

The Impact of Interferon on Interferon-Related Genes in Polycythemia Vera and Allied Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only